IP Library Granted Patent US 8,642,094
Granted Patent B2
US 8,642,094 · App. 12/434,289 · Granted Feb 4, 2014

Synergistic pharmaceutical composition, method of making same and use of same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,094
App. No.
12/434,289
Granted
Feb 4, 2014
Kind
B2
Abstract

A medicinal combination of herbs, herbal extracts, and their chemical constituents that is synergistically effective for promoting human and veterinary health. The combination is a blood lipid level lowering synergistic composition comprising Ku ding cha, berberine or a berberine-containing plant extract, and other optional active ingredients. Methods of extraction and combination in synergistic amounts are also disclosed. The compositions according to the present invention may be used to treat or reduce the chance of contracting or the progression of a number of diseases or conditions in a subject, particularly cardiovascular diseases.

Claims (25)

1. A synergistic blood lipid lowering composition comprising synergistically effective amounts of HL and KDC, wherein the weight ratio of HL to KDC is between about 25% and 75%, wherein the HL is a Huanglian extract obtained by a method comprising extraction of Coptis chinensis with water or ethanol, and wherein the KDC is a Ku Ding Cha extract obtained by a method comprising extraction of Ilex kudingcha with water, ethanol or ethyl acetate.

2. The composition of claim 1 , further comprising an effective amount of a hawthorn extract.

3. The composition of claim 1 , wherein the weight ratio of HL to KDC is between 33% and 67%.

4. The composition of claim 3 , wherein the weight ratio of HL to KDC is between 40% and 60%.

5. The composition of claim 4 , wherein the weight ratio of HL to KDC is about 1:1.

6. The composition of claim 1 , wherein the composition further comprises a carrier which is a food or beverage.

7. The composition of claim 1 in combination with another medicament or with one or more pharmaceutical acceptable carriers for the lowering of blood lipid levels.

8. The composition of claim 7 , wherein the carrier is a food or a beverage.

9. A method of lowering the blood lipid levels in a patient in need of such lowering, comprising administering to the patient an effective amount of the composition according to claim 1 .

10. The method of claim 9 , wherein the composition is administered orally.

11. The method of claim 9 , wherein the composition is orally administered to the patient in a food or beverage.

12. The method of claim 9 , wherein the blood lipid levels that are lowered comprise triglyceride levels.

13. The method of claim 9 , wherein the blood lipid levels that are lowered comprise low-density-lipoprotein cholesterol levels.

14. The method of claim 9 , wherein the blood lipid levels that are lowered comprise total cholesterol levels.

15. The method of claim 9 , wherein the mammal is a human.

16. The composition of claim 1 , wherein the HL is from Coptis chinensis Franch.

17. The composition of claim 1 , wherein the KDC is from Ilex kudingcha C. J. Tseng ( Aquifoliaceae ).

18. The composition of claim 1 , wherein the blood lipids are triglycerides, low-density-lipoprotein cholesterol or total cholesterol.

19. The composition of claim 1 , wherein the method for obtaining the Ku Ding Cha extract comprises extraction of Ilex kudingcha with ethanol to obtain a first extract, drying the first extract to obtain a dried extract, dissolving the dried extract in water to provide a resuspended extract, extracting the resuspended extract with ethyl acetate and separating the ethyl acetate phase to provide the Ku Ding Cha extract.

20. The composition of claim 1 , wherein the method for obtaining the Ku Ding Cha extract comprises extraction of Ilex kudingcha with ethanol to obtain a first extract, drying the first extract to obtain a dried extract, dissolving the dried extract in water to provide a resuspended extract, extracting the resuspended extract with ethyl acetate and separating the aqueous phase to provide the Ku Ding Cha extract.

21. The composition of claim 1 , wherein the Huanglian extract is obtained by a method comprising extraction of Coptis chinensis with water and the Ku Ding Cha extract is obtained by a method comprising extraction of Ilex kudingcha with water.

22. The composition of claim 1 , wherein the HL extract is obtained by a method comprising extraction of Coptis chinensis with ethanol and the Ku Ding Cha extract is obtained by a method comprising extraction of Ilex kudingcha with ethanol.

23. The composition of claim 1 , wherein the Huanglian extract is obtained by a method comprising extraction of Coptis chinensis with ethanol and the Ku Ding Cha extract is obtained by a method comprising extraction of Ilex kudingcha with ethyl acetate.

24. The composition of claim 1 , wherein the Huanglian extract is obtained by a method comprising extraction of Coptis chinensis with ethanol, and wherein the Ku Ding Cha extract is obtained by a method comprising extraction of Ilex kudingcha with ethanol to obtain a first extract, drying the first extract to obtain a dried extract, dissolving the dried extract in water to provide a resuspended extract, extracting the resuspended extract with ethyl acetate and separating the ethyl acetate phase to provide the Ku Ding Cha extract.

25. The composition of claim 1 , wherein the Huanglian extract is obtained by a method comprising extraction of Coptis chinensis with ethanol, and wherein the Ku Ding Cha extract is obtained by a method comprising extraction of Ilex kudingcha with ethanol to obtain a first extract, drying the first extract to obtain a dried extract, dissolving the dried extract in water to provide a resuspended extract, extracting the resuspended extract with ethyl acetate and separating the aqueous phase to provide the Ku Ding Cha extract.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Apr 17, 2024
From: BARCLAYS BANK PLC
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0587 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0596 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 049672/0652) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0618 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0651 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 060346/0705) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2023
From: VALEANT CANADA LP
To: BAUSCH HEALTH, CANADA INC.
Reel/Frame 062373/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2023
From: BAUSCH HEALTH, CANADA INC.
To: BAUSCH + LOMB CORPORATION
Reel/Frame 062374/0174 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
CERTIFICATE OF AMALGAMATION Recorded Jul 17, 2017
From: AFEXA LIFE SCIENCES INC.
To: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Reel/Frame 043211/0502 →
REDACTED ASSET TRANSFER AGREEMENT Recorded Jul 17, 2017
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: VALEANT CANADA LP
Reel/Frame 043211/0575 →